StockData
iBio, Inc. logo

iBio, Inc. (IBIO) stock

IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$0.75+0.04 (+5.86%)

Close on Nov 17, 2026Market cap $48.11MP/E –Yield –

iBio gross margin

Gross margin is gross profit as a percentage of revenue.

iBio's gross margin for the twelve months ending Jun 30, 2022 was 115.0%. For fiscal 2022 it was 115.0%, against 38.3% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2022Jun 30, 2022115.0%+76.7
FY2021Jun 30, 202138.3%−18.7
FY2020Jun 30, 202057.1%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q3 FY2022CQ1 2022Mar 31, 2022105.3%+31.4
Q4 FY2021CQ2 2021Jun 30, 202161.9%−11.4
Q3 FY2021CQ1 2021Mar 31, 202135.6%+25.1
Q2 FY2021CQ4 2020Dec 31, 202070.1%–
Q1 FY2021CQ3 2020Sep 30, 202073.9%–
Q4 FY2020CQ2 2020Jun 30, 202073.3%–
Q3 FY2020CQ1 2020Mar 31, 202010.4%–

More iBio figures

See a number that looks wrong?